JP2012136529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012136529A5 JP2012136529A5 JP2012030227A JP2012030227A JP2012136529A5 JP 2012136529 A5 JP2012136529 A5 JP 2012136529A5 JP 2012030227 A JP2012030227 A JP 2012030227A JP 2012030227 A JP2012030227 A JP 2012030227A JP 2012136529 A5 JP2012136529 A5 JP 2012136529A5
- Authority
- JP
- Japan
- Prior art keywords
- ephrin
- drug
- subject
- receptor antagonist
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100033942 Ephrin-A4 Human genes 0.000 claims 3
- 108010043938 Ephrin-A4 Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 102100033941 Ephrin-A5 Human genes 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 101000925251 Homo sapiens Ephrin-A5 Proteins 0.000 claims 1
- 230000028600 axonogenesis Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004905148A AU2004905148A0 (en) | 2004-09-08 | A method of treatment and agents useful for same | |
| AU2004905148 | 2004-09-08 | ||
| US64796805P | 2005-01-27 | 2005-01-27 | |
| US60/647,968 | 2005-01-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530543A Division JP5094395B2 (ja) | 2004-09-08 | 2005-09-08 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012136529A JP2012136529A (ja) | 2012-07-19 |
| JP2012136529A5 true JP2012136529A5 (en:Method) | 2012-08-30 |
Family
ID=36036018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530543A Expired - Fee Related JP5094395B2 (ja) | 2004-09-08 | 2005-09-08 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
| JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530543A Expired - Fee Related JP5094395B2 (ja) | 2004-09-08 | 2005-09-08 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080254023A1 (en:Method) |
| EP (1) | EP1793854A4 (en:Method) |
| JP (2) | JP5094395B2 (en:Method) |
| CA (1) | CA2579352A1 (en:Method) |
| NZ (1) | NZ553273A (en:Method) |
| WO (1) | WO2006026820A1 (en:Method) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| NZ553273A (en) * | 2004-09-08 | 2009-11-27 | Univ Melbourne | Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling |
| KR20090029261A (ko) * | 2006-07-13 | 2009-03-20 | 노파르티스 아게 | 신경계 장애의 치료에서의 트리플루오로메틸-치환 벤즈아미드의 용도 |
| US8530181B2 (en) | 2007-11-15 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase |
| JP5508857B2 (ja) * | 2007-11-30 | 2014-06-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 新規活性を有するＥｐｈＡ４ポリペプチドおよびその用途 |
| EP2260864A1 (en) * | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| DK2653552T3 (en) | 2010-12-17 | 2017-01-16 | Eisai R&D Man Co Ltd | SCREENING METHOD USING GELATINASE-MEDIATED EphA4 DIVISION REACTION AS INDICATOR |
| US9784751B2 (en) | 2011-04-25 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain |
| WO2016011201A2 (en) * | 2014-07-15 | 2016-01-21 | Sanford Burnham Prebys Medical Discovery Institute | Epha4 cyclic peptide antagonists for neuroprotection and neural repair |
| RU2651756C1 (ru) * | 2017-05-10 | 2018-04-23 | Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ | Препарат для предотвращения образования глиальных рубцов |
| MY207780A (en) | 2019-07-01 | 2025-03-18 | Eisai R&D Man Co Ltd | Anti-epha4 antibody |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) * | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| AU766077C (en) * | 1998-11-20 | 2004-10-07 | Genentech Inc. | Uses for Eph receptor antagonists and agonists to treat vascular disorders |
| WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| WO2004041197A2 (en) * | 2002-11-01 | 2004-05-21 | Case Western Reserve University | Methods of inhibiting glial scar formation |
| WO2005056766A2 (en) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
| NZ553273A (en) * | 2004-09-08 | 2009-11-27 | Univ Melbourne | Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling |
-
2005
- 2005-09-08 NZ NZ553273A patent/NZ553273A/en not_active IP Right Cessation
- 2005-09-08 JP JP2007530543A patent/JP5094395B2/ja not_active Expired - Fee Related
- 2005-09-08 EP EP05778955A patent/EP1793854A4/en not_active Withdrawn
- 2005-09-08 CA CA002579352A patent/CA2579352A1/en not_active Abandoned
- 2005-09-08 US US11/662,355 patent/US20080254023A1/en not_active Abandoned
- 2005-09-08 WO PCT/AU2005/001363 patent/WO2006026820A1/en not_active Ceased
-
2012
- 2012-02-15 JP JP2012030227A patent/JP2012136529A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012136529A5 (en:Method) | ||
| IL274602A (en) | Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia | |
| EP2406765A4 (en) | DEVICE FOR ADMINISTERING A MEDICAMENT TO A PATIENT WITH RESTRICTED PATIENT-SIDED ACCESS TO THE MEDICAMENT IN THE CASE OF CONTRAINDICATIONS AND APPLICATION METHOD THEREFOR | |
| EP4674482A3 (en) | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof | |
| HUE061596T2 (hu) | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben | |
| MX2013006591A (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| JP2012126725A5 (en:Method) | ||
| CN104812762A8 (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
| PT2604610T (pt) | Derivado cetona de ftalazinona, processo para a sua preparação e seu uso farmacêutico | |
| BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
| BR112015003376A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente | |
| EP2742155A4 (en) | BIOMARKER FOR ALZHEIMER'S DISEASE AND / OR COGNITIVE LIGHT DISORDER, AND USE THEREOF | |
| IL218674A (en) | Compounds that inhibit lrrk2 kinase activity, pharmacological preparations containing them, and their use in the preparation of Parkinson's disease drugs | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2013014622A5 (en:Method) | ||
| HUE038313T2 (hu) | Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban | |
| BR112013011480A2 (pt) | método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer | |
| SI2655375T1 (sl) | Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba | |
| EA201071204A1 (ru) | Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности | |
| CL2013001943A1 (es) | Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma. | |
| IL232764A (en) | Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease | |
| BRPI1008727A2 (pt) | derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos | |
| WO2011141488A3 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| EP3157447A4 (en) | Identifying a target anatomic location in a subject's body, and delivering a medicinal substance thereto | |
| EP3162804A8 (en) | New benzodiazepine derivative and use thereof |